Cargando…

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)

BACKGROUND: Chemotherapy added to anti-HER2 agents (H) is the treatment of choice in patients with HER2+ early breast cancer. However, HER2+ tumours are clinically and biologically heterogeneous, and treatment response varies significantly by hormone receptor (HR) status and molecular subtype. Predi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Risi, Emanuela, Biagioni, Chiara, Benelli, Matteo, Migliaccio, Ilenia, McCartney, Amelia, Bonechi, Martina, Guarducci, Cristina, Hilbers, Florentine, Di Cosimo, Serena, Huober, Jens, Romagnoli, Dario, Boccalini, Giulia, Vitale, Stefania, Sotiriou, Christos, Biganzoli, Laura, Di Leo, Angelo, Malorni, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906346/ https://www.ncbi.nlm.nih.gov/pubmed/31853266 http://dx.doi.org/10.1177/1758835919891608

Ejemplares similares

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
por: Chumsri, Saranya, et al.
Publicado: (2022)

Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
por: Di Cosimo, Serena, et al.
Publicado: (2020)

What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
por: Pizzamiglio, Sara, et al.
Publicado: (2021)

End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO
por: Di Cosimo, Serena, et al.
Publicado: (2023)

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
por: Rediti, Mattia, et al.
Publicado: (2023)

Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
por: Galardi, Francesca, et al.
Publicado: (2021)

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
por: McCartney, Amelia, et al.
Publicado: (2019)

Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
por: Guarducci, Cristina, et al.
Publicado: (2018)

Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer
por: Vignoli, Alessia, et al.
Publicado: (2021)

ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data
por: Romagnoli, Dario, et al.
Publicado: (2018)

PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2022)

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy
por: Bonechi, Martina, et al.
Publicado: (2018)

A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
por: Malorni, Luca, et al.
Publicado: (2016)

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
por: Rossi, Lorenzo, et al.
Publicado: (2018)

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
por: De Santo, Irene, et al.
Publicado: (2019)

Cell-Free DNA-Methylation-Based Methods and Applications in Oncology
por: Galardi, Francesca, et al.
Publicado: (2020)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2021)

Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
por: Migliaccio, Ilenia, et al.
Publicado: (2015)

The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018)

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
por: Rossi, Lorenzo, et al.
Publicado: (2019)

Charting differentially methylated regions in cancer with Rocker-meth
por: Benelli, Matteo, et al.
Publicado: (2021)

A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting
por: Di Donato, Samantha, et al.
Publicado: (2021)

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial
por: Lambertini, Matteo, et al.
Publicado: (2020)

Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?
por: McCartney, Amelia, et al.
Publicado: (2018)

Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors
por: McCartney, Amelia, et al.
Publicado: (2020)

Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification
por: McCartney, Amelia, et al.
Publicado: (2019)

Glucose Metabolic Reprogramming of ER(+) Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
por: Lorito, Nicla, et al.
Publicado: (2020)

Risk assessment of disease recurrence in early breast cancer: A serum metabolomic study focused on elderly patients
por: Risi, Emanuela, et al.
Publicado: (2022)

NEO E-vita—NEO era!
por: Jakob, Heinz, et al.
Publicado: (2022)

Neo-Salvarsan
Publicado: (1912)

Travel photography : a complete guide to how to shoot and sell /
por: McCartney, Susan
Publicado: (1992)

Jeremy Hunt’s bizarre ideas show that he doesn’t understand general practice
por: McCartney, Margaret
Publicado: (2014)

Margaret McCartney: What use is mass flu vaccination?
por: McCartney, Margaret
Publicado: (2014)

Margaret McCartney: Passing the patient
por: McCartney, Margaret
Publicado: (2016)

Margaret McCartney: Glasgow’s lost hospital beds
por: McCartney, Margaret
Publicado: (2016)

Margaret McCartney: Stop playing politics with illegal drug use
por: McCartney, Margaret
Publicado: (2014)

Margaret McCartney: The Care Quality Commission is not fit for purpose
por: McCartney, Margaret
Publicado: (2014)

Margaret McCartney: Industry’s interest in diagnosing more dementia
por: McCartney, Margaret
Publicado: (2014)

Margaret McCartney: Do patients know that their records aren’t private?
por: McCartney, Margaret
Publicado: (2014)

Benefits, harms and evidence – reflections from UK primary healthcare
por: McCartney, Margaret
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fbc2k2vjsvb0laipblvbuuv3e4